Pharma / Biotech

Adolescent Cancer Survivors Face an Uphill Toxicity Fight

Aggressive identification and treatment strategies have led to an overall cure rate for childhood malignancies of greater than 80%, but an increasing number of surviving patients are developing therapy-related toxicities later in life.

Source link

Related posts

Phase I dose-escalation study to determine the safety, tolerability, preliminary efficacy and pharmacokinetics of an intratumoral injection of tigilanol tiglate (EBC-46).


AMOXICILLIN Powder, For Suspension [NuCare Pharmaceuticals,Inc.]


Transitions of Care Workflow Shows Its Worth


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy